Archival Issues
Volume 19, 2017
Volume 18, 2016
Volume 17, 2015
Volume 16, 2014
Volume 15, 2013
Volume 14, 2012
Volume 13, 2011
Volume 12, 2010
Volume 11, 2009
Volume 10, 2008
Volume 9, 2007
Volume 8, 2006
Volume 7, 2005
Volume 6, 2004
Volume 5, 2003
Volume 4, 2002
Volume 3, 2001
Volume 2, 2000
Volume 1, 1999
Journal Abstract
A Comparison of Complications Requiring Return to Theatre in Hip and Knee Arthroplasty Patients Taking Enoxaparin versus Rivaroxaban for Thromboprophylaxis
GS Chahal , A Saithna, M Brewster , J Gilbody , S Lever, WS Khan, P Foguet
Ortop Traumatol Rehabil 2013; 15(2):125-130
ICID: 1045953
Article type: Original article
IC™ Value: 3.00
Abstract provided by Publisher
There is no consensus on the optimal form of venous thromboembolic prophylaxis treatment in hip and knee arthroplasty patients, or on the safety and complication profile of the available chemical prophylaxis modalities. In this study we aimed to measure the return to theatre rate for any cause related to wound complications in patients undergoing total hip replacement and total knee replacement, and compare these rates between patients on oral Rivaroxaban 10mg OD and subcutaneous Enoxaparin 40mg OD in our department. There were a total of 387 patients included in the study; 227 patients in group 1, who received Enoxaparin 40mg OD, and 160 patients in group 2, who received Rivaroxaban 10mg OD. The primary outcome measure was re-operation rate due to wound complications. Secondary outcome measures were infection rate, incidence of deep vein thrombosis, pulmonary emboli, duration of hospital stay, change in haemoglobin and haematocrit and blood transfusion rate. In this retrospective cohort study we found that patients who received Rivaroxaban were more than twice as likely to return to theatre for wound complications compared to patients receiving Enoxaparin. Although not statistically significant, this increase is in line with previous studies. Infection rates increased from 0.9% to 1.9% after the introduction of Rivaroxaban and microbiologically confirmed superficial infections rose from 1.3% to 3.1% after Rivaroxaban was introduced in our unit. These rises were not statistically significant. Our study highlights the need for large randomised controlled trials to assess post-operative complications following the introduction of Rivaroxaban for post-arthroplasty thromboprophylaxis.

ICID 1045953

DOI 10.5604/15093492.1045953
PMID 23652532 - click here to show this article in PubMed

Related articles
  • in IndexCopernicus™
         prophylaxis [77 related records]
         venous thromboembolism [5 related records]
         rivaroxaban [0 related records]
         enoxaparin [10 related records]
         Arthroplasty [34 related records]
         complications [209 related records]

  • Related articlesin PubMed database
  • in PubMed database [ related records]


    Copyright © Ortopedia Traumatologia Rehabilitacja  2017
    Page created by Index Copernicus Ltd. All Rights reserved.